|
|
||||||||
Ann Thorac Surg 2006;82:769-770
© 2006 The Society of Thoracic Surgeons
Department of Cardiovascular Surgery, Shizuoka Medical Center, 762-1 Nagasawa, Shimizu-cho, Sunto-gun, Shizuoka, 411-8611, Japan
(Email: kfgth973{at}ybb.ne.jp).
We read with great interest the article by Parolari and colleagues [1]. All five studies referred in the meta-analysis are cohort studies. When risks between groups in cohort studies are compared, the appropriate method is to calculate the relative risk (RR). The odds ratio (OR), used in the meta-analysis by Parolari and colleagues [1], is often used in case-control studies and is approximately equal to the RR only when the incidence of the event is low. However, the incidence of postoperative graft occlusion is too high (16% in the off-pump coronary artery bypass surgery [OPCAB] group vs 12% in the standard coronary artery bypass grafting [CABG] group) to justify the use of the OR. Therefore we repeated a meta-analysis using RR rather than OR.
Both separate pooled analyses using a random-effect model of the two low-quality trials [2, 3] (RR, 2.22; 95% CI, 0.51 to 9.59; p = 0.29; significant heterogeneity [p = 0.02]) and the three high-quality trials [46] (RR, 1.59; 95% CI, 0.99 to 2.57; p = 0.06; no heterogeneity [p = 0.85]) demonstrated that OPCAB had no impact on risk of graft occlusion. On the other hand, pooled analysis of all five trials [26] demonstrated a statistically significant 56% increase in risk of graft occlusion with OPCAB relative to CABG (RR, 1.56; 95% CI, 1.04 to 2.35; p = 0.03; no heterogeneity [p = 0.14]). To assess the impact of qualitative heterogeneity in trial design and patient selection on the pooled effect estimate, we performed several sensitivity analyses by excluding individual trials one at a time and re-calculating the pooled RR estimates for the remaining trials. Exclusion of either the trial by Khan and colleagues [2], the trial by Widimsky and colleagues [3], or the trial by Nathoe and colleagues [5] from the analysis of all five trials did not substantively alter the overall result. However, exclusion of either the trial by Lingaas and colleagues [4] or the trial by Puskas and colleagues [6] demonstrated that OPCAB had no impact on risk of graft occlusion.
In the meta-analysis using OR by Parolari and colleagues [1], a statistically significant increased risk of graft occlusion in the OPCAB group was demonstrated, both when all trials were analyzed together and when low-quality and high quality trials were analyzed separately. Nevertheless, in our re-analysis using RR more appropriate than OR, the statistically significant increased risk vanished when low-quality and high-quality trials were analyzed separately, and in two of five sensitivity analyses.
| References |
|---|
|
|
|---|
Related Article
This article has been cited by other articles:
![]() |
A. Parolari, F. Alamanni, F. Veglia, E. Tremoli, and P. Biglioli Reply Ann. Thorac. Surg., August 1, 2006; 82(2): 770 - 771. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |